Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S339000, C546S268100, C546S268400
Reexamination Certificate
active
07078419
ABSTRACT:
Disclosed are compounds of formula (I)Where Ar1, X, Y, Q, W, R3, R4, R5, R6and Ryare defined herein. The compounds of the invention inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. The compounds are also useful for treating diseases or conditions related to oncology and anticoagulant or fibrinolytic therapy. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 2005/0004176 (2005-01-01), Dyckman et al.
patent: 4302051 (1994-07-01), None
patent: 2000 256358 (2000-09-01), None
patent: WO96/16954 (1996-06-01), None
patent: WO 96/32382 (1996-10-01), None
patent: WO 97/29105 (1997-08-01), None
patent: WO 98/22452 (1998-05-01), None
patent: WO 99/01423 (1999-01-01), None
patent: WO 99/43672 (1999-09-01), None
patent: WO 99/45002 (1999-09-01), None
patent: WO 99/51580 (1999-10-01), None
patent: WO 00/06550 (2000-02-01), None
patent: WO 00/24735 (2000-05-01), None
patent: WO 00/26197 (2000-05-01), None
patent: WO 00/44737 (2000-08-01), None
patent: WO 00/75120 (2000-12-01), None
patent: WO 01/44445 (2001-06-01), None
patent: WO 01/51456 (2001-07-01), None
patent: WO 01/53274 (2001-07-01), None
patent: WO 02/24635 (2002-03-01), None
patent: WO 02/28820 (2002-04-01), None
patent: WO 02/30894 (2002-04-01), None
patent: WO 03/02910 (2003-01-01), None
patent: WO 03/22820 (2003-03-01), None
patent: WO 03/030902 (2003-04-01), None
patent: WO 03/063781 (2003-08-01), None
English Translation for DE 43 02 051 A1.
Abstract of JP 2000/256358 Pyrazole Derivative- Sep. 19, 2000—Kubota, K., et al—Yamanouchi Pharmacutical Co. Ltd.
Abstract of WO 00/06550—Phenylazole Compounds, Process for Producing the Same and Drugs for Hyperlipemia, Feb. 10, 2000, Kunihito, I., et al.
Abstract WO 99/45002—Benzofuran Derivatives, Sep. 10, 1999, Ichiro, M., et al.
Abstract of WO 98/22452—Benzofuran Derivatives, May 28, 1998, Etsuo, O., et al.
Abstract of WO 97/29105—Benzofuran-7-Yluracil Derivatives and Herbicides, Masahiro, M., et al.
“Tumor Necrosis Factor Inhibitors”; Early Alert Report, Fall 2000.
van Heel, D. A et al; “Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kB transcription factors”; Human Molecular Genetics (2002): 1281-1289.
Webb, G. R., et al; “Chondrocyte tumor necrosis factor receptors and focal loss of cartilage in osteoarthritis”; Osteoarthritis and Cartilage, 1997, 5, 427-437.
Raine, C. S. et al; “Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque”; Rev. Neurol. (Paris) 1998, 154, 577-585.
Ma, J. J. et al; “Genetic Contribution of the Tumor Necrosis Factor Region in Guillan-Barré Sundrome”; Annals of Neurology, 1998, 44, 815-818.
Chodorowska, C. et al; “Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment”; J. Eur. Acad. Dermatollogy And Venereology, 1998, 10, 147-151.
Nagler, A. et al; “Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation”; Cytokines, Cellular & Molecular Ther., 1998, 4, 161-167.
Robak, E., “Association of Interferon gamma, Tumor Necrosis Factor alpha and Interleukin 6 Serum Levels with Systemic Lupus Erythematosus Activity”; Archivum Immunologiae et Therapiae Experimentalis, 1998, 46, 375-380.
Tashiro, H. et al; “Role ofcytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty”; Coronary Artery Disease, 12: 107-113.
Brown, G. R. et al; “Lymphoid Hyperplasia, CD45RBhigh to CD45RBlow T-cell imbalance, and suppression of Type I diabetes mellitus result fromTNF blockade in NOD-NOD-scid adoptive T cell transfer”; Diabetologia, 1998, 41, 1502-1510.
Soltys, J. et al; “Modulation of Endotoxin- and Enterotosin-Induced Cytokine Release by In Vivo Treatment with beta-(1,6)-Branched beta-(1,3)-Glucan”; Infection and Immunity, 1999, 244-252.
Bjugstad, K. B. et al; “Preventive actions of a synthetic antioxidant in a novel animalmodel of AIDS dementia 1”; Brain Research, 1998, 795, 349-357.
Chou, R. C. et al; “Adrenergic regulation of macrophage-derived tumornecrosis factor-alpha generation durng a chronic polyarthritis pain model”; J. Neuroimmunol., 1998, 82, 140-148.
Mueller, G. et al; “Is Cytokine Expression Responsible for Differences Between Allergens and Irritants?”; American J. of Contact Dermitis, vol. 7, No. 3 (Sep.), 1996, 177-184.
Elhage, R. et al.; “Differential Effects of Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor Binding Protein on Fatty-Streak Formation in Apolipoprotein E-Deficient Mice”; Circulation, 1998, 97:242-244.
Ryffel, B. et al.; “Failure to induce anti-glomerular basement membrane glomerulonephritis in TNFalpha/beta deficient mice”; Int. J. Exp. Path., 1998, 79, 453-460.
Mitsui, Y. et al; “The expression of proinflammatory cytokine mRNA in the sciatic-tibial nerve of ischemia-reperfusion injury”; Brain Research, 844 (1999), 192-195.
Li, D. et al, “Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction” Amer. Heart Journal, 1999, 137, 1145-1152.
Yeh, F. L. et al, “Changes in serum tumour necrosis factor-alpha in burned patients”; Burns, 1997, 23, 6-10.
Renzetti, L.M. et al; “Ro 45-2081.a TNF receptor fusion protein, prevents inflammatory responses in the airways”; Inflamm. Res. 1997, 46, Suppl. 2, S143-S144.
Lemay, S. et al; “Prominent and Sustained Up-regulation of gp 130-Signaling Cytokines and of the Chemokine MIP-2 in Murine Renal Ischemia-Reperfusin Injury1”; Transplantation, vol. 69, No. 5, (2000), 959-963.
Boerjesson, A. et al; “TNF-alpha stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats”; Am. J. Physiol. Lung Cell. Mol. Physiol., (2000) 278:L3-L12.
Kurokouchi, K. et al; “TNF-alpha Increases Expression of IL-6 and ICAM-1 Genes Through Activation of NFkB in Osteoblast-like ROS17/2.8 Cells”; J. Bone and Mineral Res., 1998, 13, 1290-1299.
Higham, M. A. et al; “Tumour necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease”; Eur. Respir J. 2000, 15:281-284.
Takabatake, N. et al; “The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-alpha System in Patients with Chronic Obstructive Pulmonary Disease”; Am. J. Respir. Crit. Care Med., vol. 161, 2000, 1179-1184.
Lee, T.H., “Cytokine networks in the pathogenesis of bronchial asthma: Implications for therapy”; J. of the Royal Coll. of Phys. of London, vol. 32, No. 1, Jan./Feb. 1998; 56-64.
Lipton, J. M. et al; “Peptide Modulation of Inflammatory Processes within the Brain”; Neuroimmunomodulation, 1998, 5, 178-183.
Branger, J. et al; “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemial”; J. Immunol. 2002, 168: 4070-4077.
Viscardi, R. M. et al; “Inflammatory Cytokine mRNAs in Surgical Specimens of Necrotizing Enterocolitis and Normal Newborn Intestine”; Pediatric. Pathol. And Lab. medicine, 1997, 17, 547-559.
Paris, M. M. et al; “The Effect of Interleukin-10 on Meningeal Inflammation in Experimental Bacterial Meningitis”; J. Infectious Dis. 1997, 176, 1239-1246.
Bahrami, S. et al; “Significance of TNF in hemorrhage-related hemodynamic alterations, organ injury, and mortality in rats”; Am. J. Physiol. 1997, 272 (Heart Circ. Physiol. 41) H
Aungst, Jr. Ronald A.
Cirillo Pier Francesco
Gao Donghong Amy
Goldberg Daniel R.
Hammach Abdelhakim
Boehringer Ingelheim Pharmaceuticals Inc.
Bottino Anthony P.
Devlin Mary-Ellen M.
Morris Michael P.
LandOfFree
Cytokine inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586184